Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Open-label Study of the Impact of Prolonged Systemic Corticosteroid Therapy on the Course and Relapse Risk of Checkpoint Inhibitor Interstitial Lung Disease (Pneumonitis) Related to the Treatment of Solid Tumors With Anti-programmed-death Type 1 Receptor or Ligand Antibodies

NCT04036721 is registered in ClinicalTrials.gov with National Institute for Tuberculosis and Lung Diseases, Poland as lead sponsor.

NCT NCT04036721
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04036721 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Open-label Study of the Impact of Prolonged Systemic Corticosteroid Therapy on the Course and Relapse Risk of Checkpoint Inhibitor Interstitial Lung Disease (Pneumonitis) Related to the Treatment of Solid Tumors With Anti-programmed-death Type 1 Receptor or Ligand Antibodies
Lead sponsor
National Institute for Tuberculosis and Lung Diseases, Poland
Phase
Phase 4
Overall status
Suspended
Start date
October 1, 2019
Completion date
February 1, 2026
Enrollment
85 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

interstitial lung disease, lung neoplasm malignant